Completed PHASE1 INTERVENTIONAL NCT00923741

Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer

An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC)

Sponsor: National Cancer Institute (NCI)

Conditions Non-Small Cell Lung Cancer

Interventions Apheresis Talactoferrin

Updated 7 times since 2017 Last updated: Jul 3, 2018 Started: Jun 19, 2008 Primary completion: Feb 1, 2010 Completion: Feb 1, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00923741, this PHASE1 trial focuses on Non-Small Cell Lung Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States